Inari Medical, Inc. (NASDAQ:NARI) Shares Bought by Algert Global LLC

Algert Global LLC grew its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 53.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,706 shares of the company’s stock after acquiring an additional 23,600 shares during the period. Algert Global LLC owned about 0.12% of Inari Medical worth $3,456,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Sei Investments Co. increased its holdings in Inari Medical by 1.3% during the 4th quarter. Sei Investments Co. now owns 57,566 shares of the company’s stock worth $2,939,000 after purchasing an additional 727 shares during the period. GAMMA Investing LLC raised its holdings in Inari Medical by 66.8% in the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company’s stock valued at $100,000 after acquiring an additional 786 shares in the last quarter. Barclays PLC lifted its stake in Inari Medical by 9.7% in the third quarter. Barclays PLC now owns 288,079 shares of the company’s stock worth $11,881,000 after acquiring an additional 25,365 shares during the last quarter. Legato Capital Management LLC acquired a new position in Inari Medical during the 4th quarter worth approximately $681,000. Finally, Asset Management One Co. Ltd. increased its position in shares of Inari Medical by 7.8% in the 4th quarter. Asset Management One Co. Ltd. now owns 66,149 shares of the company’s stock valued at $3,504,000 after purchasing an additional 4,795 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analyst Ratings Changes

NARI has been the subject of a number of analyst reports. Canaccord Genuity Group reiterated a “hold” rating and set a $80.00 target price (up previously from $74.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Wells Fargo & Company reissued an “equal weight” rating and set a $80.00 target price (up previously from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Baird R W downgraded Inari Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 7th. William Blair reissued a “market perform” rating on shares of Inari Medical in a report on Tuesday, January 7th. Finally, Piper Sandler upped their target price on shares of Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $69.22.

Inari Medical Stock Performance

NASDAQ:NARI opened at $79.97 on Wednesday. Inari Medical, Inc. has a 12-month low of $39.76 and a 12-month high of $79.99. The stock’s 50 day simple moving average is $79.97 and its 200-day simple moving average is $68.76. The firm has a market cap of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.